"Sirolimus" and "Hydroxychloroquine"
Phase 1Small molecule
"Sirolimus" and "Hydroxychloroquine" is one of 14 small molecule programs targeting Lymphangioleiomyomatosis. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Lymphangioleiomyomatosis
#DrugCompanyPhaseTrials
1Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Proair HFA
GGlaxo Dba Glaxosmithkline
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Afinitor
NovartisPhase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Femara
NovartisPhase 2
Aristan
NNational Cancer Institute (NCI)
Phase 2
Ofev
Boehringer IngelheimPhase 2
Sandostatin
Sun PharmaPhase 2
Claritin
PPerrigo Company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lymphangioleiomyomatosis1 trial
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Completed·—·Phase 1·NCT01687179·14 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- BBrigham and Women's Hospital